• Skip to primary navigation
  • Skip to main content
  • Skip to footer
ElevateBio

ElevateBio

Powering the creation of cell & gene therapies at a speed the world deserves.

  • Resources
    • Resources Overview
    • Elevated Insights
    • Presentations & Publications
    • Whitepapers
  • Media
    • Media Overview
    • Press Releases
    • Featured News
  • Facilities
  • Careers
  • Contact
  • Search
  • Manufacturing & Discovery Services
    • Manufacturing & Discovery Services Overview
    • Gene Editing Design & Optimization
    • Process Development
    • Analytical Development
    • cGMP Manufacturing
    • Next-Generation Sequencing
    • Quality
    • Regulatory CMC
    • Certifications & Compliance
    • Generative AI
  • Technologies
    • Technologies Overview
    • Gene Editing
    • Viral and Non-Viral Delivery
    • Messenger RNA (mRNA)
    • Induced Pluripotent Stem Cells (iPSCs)
  • Advanced Therapies
  • Partner With Us
  • About
    • About Overview
    • Our Journey
    • Our Team
    • Culture of Expedition
    • Careers
    • Investors
  • Resources
    • Resources Overview
    • Elevated Insights
    • Presentations & Publications
    • Whitepapers
  • Media
    • Media Overview
    • Press Releases
    • Featured News
  • Facilities
  • Careers
  • Contact
  • Manufacturing & Discovery Services

    Manufacturing & Discovery Services Overview

    Capabilities & Services
    • Gene Editing Design & Optimization
    • Process Development
    • Analytical Development
    • cGMP Manufacturing
    • Next-Generation Sequencing
    Expertise
    • Quality
    • Regulatory CMC
    • Certifications & Compliance
    • Generative AI
  • Technologies
    • Technologies Overview
    • Gene Editing
    • Viral and Non-Viral Delivery
    • Messenger RNA (mRNA)
    • Induced Pluripotent Stem Cells (iPSCs)
  • Advanced Therapies
  • Partner With Us
  • About
    • About Overview
    • Our Journey
    • Our Team
    • Culture of Expedition
    • Careers
    • Investors

// Nov 03, 2026 | Fierce Biotech

Reengineering the Economics of Autologous Cell Therapy

Katie Shannon, M.S. LinkedIn

VP, Site Head, BaseCamp Pittsburgh

Steven Binninger

Head of Emerging Technology & Business Ventures, Sartorius

Masaki Yamada

Head of Product, Invert

David Kuninger

Director, R&D Cell Biology, Thermo Fisher Scientific

Overview

Autologous cell therapies have demonstrated their clinical potential, but manufacturing economics remain a significant barrier to broader access and long-term commercial sustainability. Meaningfully reducing cost will require more than incremental process improvements or any single technology. It will require manufacturers to rethink how therapies are produced, how processes are monitored and optimized, and where the largest costs reside. 

This roundtable explores several of the technology and operational strategies that could have the greatest impact on the economics of autologous cell therapy manufacturing, including automation and parallel processing, artificial intelligence, and raw material strategy. 

Webinar Download

Enter your information below to view the Webinar for this presentation

About the Speaker

Katie Shannon, M.S.

VP, Site Head, BaseCamp Pittsburgh

Katherine has over 20 years of experience in biomanufacturing operations including multiple new facility startups. She currently serves as Site Head, BaseCamp Pittsburgh and is responsible for supply chain, facilities, technical operations, manufacturing, and program management.

Prior to ElevateBio, Katherine held several Senior Director roles at Thermo Fisher Scientific, where she oversaw global manufacturing technology for thirty sites and managed engineering, portfolio management, and strategy across five viral vector manufacturing facilities. Prior to that, Katherine led the Global Engineering function at Brammer Bio and held roles at Biogen and Sanofi Pasteur enabling tech transfer and commercial manufacturing.

Education and Accomplishments

Katherine received her M.S. in Engineering Management from the University of Wisconsin-Madison and her B.S. in Chemical Engineering from Lehigh University.

LinkedIn

Steven Binninger

Head of Emerging Technology & Business Ventures, Sartorius

Steven Binninger is Head of Emerging Technology & Business Ventures at Sartorius, where he focuses on identifying, developing, and commercializing innovative technologies, including the Eveo® Cell Therapy Platform, that advance bioprocessing and next-generation medicines. With more than a decade of experience in biotechnology, cell and gene therapy, and process development, he has led technology innovation, strategic partnerships, and commercialization initiatives across the life sciences industry. Prior to joining Sartorius, Steve held leadership roles at Autolomous, ScaleReady, and Fresenius Kabi, supporting the development and scale-up of advanced therapy manufacturing technologies.

Masaki Yamada

Head of Product, Invert

Masaki Yamada is Head of Product at Invert, where he leads the development of AI agents to help bioprocess teams move faster from data to decisions. His work sits at the intersection of process engineering, data systems, and applied AI in manufacturing environments, informed by his wet-lab experience in strain engineering and process development at NASA Ames, Genentech, and Culture Biosciences.

David Kuninger

Director, R&D Cell Biology, Thermo Fisher Scientific

David is a seasoned biotechnology professional with 19+ years experience in product development and commercialization with Thermo Fisher Scientific. He leads the “Cells as Models and Translational Culture” R&D organization within the Cell Biology Business Unit which is responsible for new product development in stem cell biology, neuroscience, ADME-Tox, patient derived tumoroid models supporting both research and cell therapy applications. His team focuses on developing culture media and reagents to enable more consistent and robust customer applications across a diverse array of biology, culture formats (2D and 3D) and scale. These products are produced under our Gibco brand and are intended for both research (RUO) and translational applications under our CTS brand. He has extensive experience in developing and commercial support of culture systems for complex biological models as well as practical know now for reductions in the use of animals and animal derived products. He also has an in-depth understanding of quality and regulatory requirements needed for GMP environment.

Footer

ElevateBio

Investors & Media

LinkedIn Twitter

© 2026 ElevateBio. All Rights Reserved.

Privacy & Cookie Policy

  • Manufacturing & Discovery Services
  • Technologies
  • Advanced Therapies
  • Partner With Us
  • About
  • Presentations & Publications
  • Elevated Insights
  • Careers
  • Facilities
  • Contact
MENU
  • Manufacturing & Discovery Services
    • Manufacturing & Discovery Services Overview
    • Gene Editing Design & Optimization
    • Process Development
    • Analytical Development
    • cGMP Manufacturing
    • Next-Generation Sequencing
    • Quality
    • Regulatory CMC
    • Certifications & Compliance
    • Generative AI
  • Technologies
    • Technologies Overview
    • Gene Editing
    • Viral and Non-Viral Delivery
    • Messenger RNA (mRNA)
    • Induced Pluripotent Stem Cells (iPSCs)
  • Advanced Therapies
  • Partner With Us
  • About
    • About Overview
    • Our Journey
    • Our Team
    • Culture of Expedition
    • Careers
    • Investors
  • Resources
    • Resources Overview
    • Elevated Insights
    • Presentations & Publications
    • Whitepapers
  • Media
    • Media Overview
    • Press Releases
    • Featured News
  • Facilities
  • Careers
  • Contact